Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q1 2011 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
AMICUS THERAPEUTICS INC. | 39 | Q2 2024 | 17.9% |
MIRATI THERAPEUTICS INC. | 36 | Q4 2023 | 17.2% |
BIOMARIN PHARMACEUTICAL INC | 34 | Q2 2024 | 8.0% |
SAREPTA THERAPUTICS INC | 31 | Q2 2024 | 14.8% |
ASCENDIS PHARMA | 31 | Q2 2024 | 9.1% |
ARGENX SE | 29 | Q2 2024 | 9.5% |
IOVANCE BIOTHERAPEUTICS INC | 29 | Q2 2024 | 9.1% |
FENNEC PHARMACEUTICALS INC | 26 | Q4 2023 | 0.4% |
MADRIGAL PHARMACEUTICALS INC | 25 | Q2 2024 | 7.7% |
XENON PHARMACEUTICALS INC | 25 | Q2 2024 | 3.6% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Spyre Therapeutics, Inc. | April 23, 2024 | 1,839,138 | 5.1% |
AMICUS THERAPEUTICS, INC. | February 14, 2024 | 27,400,000 | 9.3% |
Apellis Pharmaceuticals, Inc. | February 14, 2024 | 13,411,111 | 9.9% |
Ascendis Pharma A/S | February 14, 2024 | 3,755,555 | 6.5% |
BIOCRYST PHARMACEUTICALS INC | February 14, 2024 | 13,050,000 | 6.4% |
CymaBay Therapeutics, Inc. | February 14, 2024 | 16,337,739 | 10.0% |
IO Biotech, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
Krystal Biotech, Inc. | February 14, 2024 | 2,565,555 | 9.1% |
Kymera Therapeutics, Inc. | February 14, 2024 | 3,775,000 | 6.8% |
MADRIGAL PHARMACEUTICALS, INC. | February 14, 2024 | 2,288,888 | 9.9% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
N-PX | 2024-08-27 |
13F-HR | 2024-08-14 |
4 | 2024-06-14 |
13F-HR | 2024-05-15 |
SC 13G/A | 2024-04-23 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.